Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
1.50% $7.46
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 796.12 mill |
EPS: | -1.080 |
P/E: | -6.91 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 106.72 mill |
Avg Daily Volume: | 0.680 mill |
RATING 2024-04-17 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.91 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.18x |
Company: PE -6.91 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-6.34 (-184.92%) $-13.80 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 6.88 - 8.04 ( +/- 7.75%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-20 | Third Rock Ventures Iv, L.p. | Sell | 162 500 | Common Stock |
2024-02-06 | Weber Barbara | Sell | 4 681 | Common Stock |
2024-02-07 | Weber Barbara | Sell | 4 457 | Common Stock |
2024-02-06 | Barry Douglas | Sell | 1 422 | Common Stock |
2024-02-07 | Barry Douglas | Sell | 1 354 | Common Stock |
INSIDER POWER |
---|
91.93 |
Last 93 transactions |
Buy: 16 052 308 | Sell: 885 960 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.46 (1.50% ) |
Volume | 0.439 mill |
Avg. Vol. | 0.680 mill |
% of Avg. Vol | 64.53 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $12.15 | N/A | Active |
---|
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.